| pubmed-article:17970038 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17970038 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
| pubmed-article:17970038 | lifeskim:mentions | umls-concept:C1367307 | lld:lifeskim |
| pubmed-article:17970038 | lifeskim:mentions | umls-concept:C0021390 | lld:lifeskim |
| pubmed-article:17970038 | lifeskim:mentions | umls-concept:C1511617 | lld:lifeskim |
| pubmed-article:17970038 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:17970038 | lifeskim:mentions | umls-concept:C0086982 | lld:lifeskim |
| pubmed-article:17970038 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:17970038 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:17970038 | pubmed:issue | 6A | lld:pubmed |
| pubmed-article:17970038 | pubmed:dateCreated | 2007-10-31 | lld:pubmed |
| pubmed-article:17970038 | pubmed:abstractText | Interleukin-6 (IL-6) is a pleiotropic cytokine with central roles in immune and inflammatory reactions. IL-6 first binds to the IL-6 receptor (IL-6R), this complex then associates with gp130, inducing dimerization and the initiation of signaling through signal transducer and activator of transcription-3 (STAT3). Notably, the combination of soluble IL-6 receptor (sIL-6R) and IL-6 stimulates cells that only express gp130 and not IL-6R, a process known as trans-signaling. In contrast, soluble gpl30 (sgp130) serves as a natural inhibitor of trans-signaling. Accumulated evidence strongly supports the hypothesis that the development and perpetuation of inflammatory bowel disease (IBD) relies on IL-6-mediated STAT3 activation on mucosal T-cells. This review looks at therapeutic strategies targeting the IL-6/STAT3 pathway in patients with IBD, including strategies involving the anti-IL-6 receptor antibody and soluble gp130Fc. | lld:pubmed |
| pubmed-article:17970038 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17970038 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17970038 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17970038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17970038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17970038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17970038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17970038 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17970038 | pubmed:issn | 0250-7005 | lld:pubmed |
| pubmed-article:17970038 | pubmed:author | pubmed-author:MitsuyamaKeii... | lld:pubmed |
| pubmed-article:17970038 | pubmed:author | pubmed-author:SataMichioM | lld:pubmed |
| pubmed-article:17970038 | pubmed:author | pubmed-author:TakedatsuHide... | lld:pubmed |
| pubmed-article:17970038 | pubmed:author | pubmed-author:MatsumotoSato... | lld:pubmed |
| pubmed-article:17970038 | pubmed:author | pubmed-author:KuwakiKotaroK | lld:pubmed |
| pubmed-article:17970038 | pubmed:author | pubmed-author:MasudaJunyaJ | lld:pubmed |
| pubmed-article:17970038 | pubmed:author | pubmed-author:YamasakiiHiro... | lld:pubmed |
| pubmed-article:17970038 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17970038 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:17970038 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17970038 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17970038 | pubmed:pagination | 3749-56 | lld:pubmed |
| pubmed-article:17970038 | pubmed:meshHeading | pubmed-meshheading:17970038... | lld:pubmed |
| pubmed-article:17970038 | pubmed:meshHeading | pubmed-meshheading:17970038... | lld:pubmed |
| pubmed-article:17970038 | pubmed:meshHeading | pubmed-meshheading:17970038... | lld:pubmed |
| pubmed-article:17970038 | pubmed:meshHeading | pubmed-meshheading:17970038... | lld:pubmed |
| pubmed-article:17970038 | pubmed:meshHeading | pubmed-meshheading:17970038... | lld:pubmed |
| pubmed-article:17970038 | pubmed:meshHeading | pubmed-meshheading:17970038... | lld:pubmed |
| pubmed-article:17970038 | pubmed:meshHeading | pubmed-meshheading:17970038... | lld:pubmed |
| pubmed-article:17970038 | pubmed:meshHeading | pubmed-meshheading:17970038... | lld:pubmed |
| pubmed-article:17970038 | pubmed:articleTitle | Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. | lld:pubmed |
| pubmed-article:17970038 | pubmed:affiliation | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Asahi-machi 67, Kurume, Japan. ibd@med.kurume-u.ac.jp | lld:pubmed |
| pubmed-article:17970038 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17970038 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:17970038 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17970038 | lld:pubmed |
